MFMuriel Fartoukh

Muriel Fartoukh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Muriel Fartoukh has a total of 366 co-authors. Here are the top co-authors by number of shared publications:

  • Antoine Parrot

    Service de Pneumologie et Oncologie Thoracique, Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Tenon, Paris, France

    13 shared publications
  • Guillaume Voiriot

    Service de Médecine Intensive Réanimation, Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Tenon, Paris, France

    8 shared publications
  • Antoine Parrot

    A Service de Pneumologie , AP-HP, Hôpitaux Universitaires de l'Est Parisien, Pôle TVAR, Hôpital Tenon , Paris , France

    7 shared publications
  • Guillaume Voiriot

    Sorbonne Université, Centre de Recherche Saint-Antoine UMRS_938 INSERM, Assistance Publique - Hôpitaux de Paris, Service de Médecine Intensive Réanimation, Hôpital Tenon, Paris, France

    6 shared publications
  • Aude Gibelin

    Service de Médecine Intensive Réanimation, Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Tenon, Paris, France

    5 shared publications
  • Antoine Khalil

    Groupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Tenon, Service de Radiologie, Sorbonne Université, Paris, France

    4 shared publications

Latest Publications

  • Open Access

    Differential impact of the pandemic first wave on chronic respiratory diseases in France

    by Muriel Fartoukh, Lucie Brolon, Marie Al Rahmoun, Alexandre Sabaté-Elabbadi, Didier Guillemot, Christian Brun-Buisson, Laurence Watier

  • Open Access

    One-year healthcare trajectories after COVID-19 hospitalisation in patients with chronic respiratory diseases: a nationwide study

    by Alexandre Sabaté-Elabbadi, Lucie Brolon, Christian Brun-Buisson, Marie Al Rahmoun, Didier Guillemot, Muriel Fartoukh, Laurence Watier

    Rationale: COVID-19 pandemic had a significant impact on patients with chronic respiratory diseases (CRD) and was associated with an increased risk of severe outcomes. However, long-term burden of COVID-19 and the dynamics on healthcare utilisation of patients with CRD remain largely unknown. Objective: The objective was to evaluate outcomes and healthcare utilisation trajectories 1 year after hospitalisation for COVID-19 in patients with CRD. Methods: Data were extracted from the French National Health Database (SNDS). All adults with CRD who had a first hospitalisation for symptomatic COVID-19 and discharged alive between March 2020 and January 2021 were included. Postdischarge care trajectories, including any hospitalisations and ambulatory care recorded in the SNDS, over a 1-year period, were analysed using state sequence analysis. Healthcare utilisation patterns between the year prior to and the year following hospitalisation were then compared, and a multinomial logistic regression analysis was performed to identify baseline CRD category associated with trajectory clusters. Results: Among the 40 066 patients with CRD discharged alive, chronic obstructive pulmonary disease was the main CRD followed by asthma, sleep apnoea and interstitial lung disease. Overall, 6913 (17.3%) died at 1 year. Proportion of days alive spent at home without any care decreased from 91.1% to 64.4%. Five distinct clusters of healthcare trajectories were identified: ‘home’ (52%) with a slight increase in healthcare utilisation, ‘home with care’ (22%) with a high healthcare utilisation, ‘extended hospitalisation’ (9.4%) in long-term care or acute care, ‘early death’ (11%) and ‘late death’ (5.1%). Asthma was more often associated with the ‘home’ trajectory, while other CRD categories were more often associated with other clusters. Conclusion: Patients with CRD hospitalised for COVID-19 had heterogeneous 1-year trajectories, characterised by increased healthcare utilisation and risk of death. Asthma was the only CRD category not associated with excess mortality or high healthcare consumption.

  • Open Access

    Severe autoimmune hemolytic anemia in ICU: a place for emergency plasma exchange? A French multicenter retrospective study

    by Jean-Baptiste Destival, Tomas Urbina, Wulfran Bougouin, Judith Leblanc, Sacha Seksik, Delphine Gobert, Vincent Bonny, Louai Missri, Jean-Luc Baudel, Juliette Bernier, et al.

    Autoimmune hemolytic anemia (AIHA) is a rare but potentially life-threatening condition requiring intensive care unit (ICU) admission in severe cases. While corticosteroids and immunosuppressants are standard treatments, their delayed efficacy limits their utility in critical settings requiring rapid hemolysis control. Plasma exchange (PlEx) may offer a rapid intervention, but its effectiveness in severe AIHA remains uncertain. This study aims to assess the clinical characteristics, outcomes, and the potential benefit of PlEx in ICU cases with severe AIHA. We conducted a multicenter retrospective cohort study including patients with severe AIHA admitted to 15 ICUs within the Assistance Publique–Hôpitaux de Paris (AP-HP) network between 2017 and 2024. Clinical, biological, and therapeutic data were collected. A multivariate logistic regression model, an analysis adjusted on a propensity score (PS) and on inverse probability of treatment weighting (IPTW) were used to identify predictors of in-ICU mortality and evaluate the association between PlEx and in-ICU mortality. One hundred forty-eight ICU stays involving severe AIHA hemolytic crises were analyzed. The median age at ICU admission was 61 {48–71} years, with a balanced sex ratio (51% male). Admission median hemoglobin was 5.2 g/dL {4.2–7.2} and in-ICU mortality was 17.6%. Risk factors for in-ICU mortality included age > 60 years, renal replacement therapy, mechanical ventilation, and high-dose intravenous methylprednisolone (HDIM). Therefore, ICU mortality was mainly driven by organ dysfunction rather than anemia severity. Standard corticosteroid therapy (1–2 mg/kg) (OR:0.19 [0.03–0.94], P = 0.05) and PlEx (OR:0.04 [0.004–0.4], P = 0.008) were associated with improved survival. The association between PlEx and outcome persisted after PS (OR: 0.04 [0.001–0.39]; P = 0.012) and IPTW (OR: 0.13 [0.02–0.55]; P = 0.011) adjustment. In this large ICU cohort, severe AIHA was associated with high mortality, driven by organ failure rather than anemia severity. PlEx are associated with survival, suggesting its potential role as a bridge to immunosuppressive therapy in selected cases. Prospective studies are needed to confirm these findings.


  • Open Access

    Severe hemoptysis: etiologies, management, and outcomes from a single-center experience over the last decade

    by Julien Dessajan, Aude Gibelin, Matthias Barral, Nina de Montmollin, Vincent Labbé, Michel Djibré, Guillaume Voiriot, Matthieu Turpin, Antoine Parrot, Muriel Fartoukh


  • Open Access

    Combined use of respiratory multiplex PCR and procalcitonin to reduce antibiotic exposure in sickle-cell adult patients with acute chest syndrome (The ANTIBIO-STA study): a randomised, controlled, open-label trial

    by Alexandre Sabaté-Elabbadi, Armand Mekontso-Dessap, François Lionnet, Aline Santin, Charlotte Verdet, Paul-Louis Woerther, Julien Lopinto, Matthieu Turpin, Alexandra Rousseau, Romane Lacoste-Badie, et al.


  • Case 327: Exogenous Lipoid Pneumonia

    by Maxens Decavèle, Jérémie Pichon, Anne Fajac, Audrey Milon, Martine Antoine, Aude Gibelin, Antoine Parrot, Muriel Fartoukh

    History: A 58-year-old male patient with an active smoking status was admitted twice to the intensive care unit (ICU) of a tertiary referral thoracic center for severe hypercapnic acute respiratory failure and persistent bilateral chest radiograph opacities that were unchanged over the course of the two ICU admissions within a 3-month period. The patient had obesity (body mass index, 36), stage 3 vascular chronic renal insufficiency, and hebephrenic schizophrenia treated with haloperidol, carbamazepine, and cyamemazine. He reported chronic dyspnea on exertion, which worsened for 6 months. At the second ICU admission, the patient was afebrile, with a blood pressure of 160/72 mm Hg and pulse oximetry of 93% on 6 L/min oxygen therapy through a nonrebreathing mask. Physical examination showed signs of respiratory failure with wheezing and active abdominal expiration, and bilateral pulmonary crackles without chest pain, hemoptysis, clubbing, or signs of cardiac failure. The patient had no peripheral lymphadenopathy and no enlarged spleen. Blood gases (on 6 L/min oxygen) showed respiratory acidosis (pH, 7.15 [normal range, 7.38–7.42]; PaO2 level, 67 mm Hg [normal range, 80–100 mm Hg]; PaCO2 level, 102 mm Hg [normal range, 38–42 mm Hg]; bicarbonate [HCO3−], 29 mmol/L [normal range, 22–27 mmol/L]). Noninvasive ventilation was initiated. Imaging performed during the second ICU hospitalization included CT and MRI of the chest without contrast enhancement, and fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT.


  • Case 327

    by Maxens Decavèle, Jérémie Pichon, Anne Fajac, Audrey Milon, Martine Antoine, Aude Gibelin, Antoine Parrot, Muriel Fartoukh

    A 58-year-old man who was an active smoker was admitted twice to the intensive care unit (ICU) of a tertiary referral thoracic center for severe hypercapnic acute respiratory failure and persistent bilateral chest radiograph opacities that were unchanged over the course of the two ICU admissions within a 3-month period (Fig 1). He had obesity (body mass index, 36 kg/m2), stage 3 vascular chronic renal insufficiency, and hebephrenic schizophrenia treated with haloperidol, carbamazepine, and cyamemazine. He reported chronic dyspnea on exertion, which worsened for 6 months. At the second ICU admission, he was afebrile, with a blood pressure of 160/72 mm Hg and pulse oximetry of 93% on 6 L/min oxygen therapy through a nonrebreathing mask. Physical examination showed signs of respiratory failure with wheezing and active abdominal expiration, bilateral pulmonary crackles without chest pain, hemoptysis, clubbing, or signs of cardiac failure. He had no peripheral lymphadenopathy and no enlarged spleen. Blood gases (on 6 L/min oxygen) showed respiratory acidosis (pH, 7.15 [normal range, 7.38-7.42]; Pao2 level, 67 mm Hg [normal range, 80-100 mm Hg]; Paco2 level, 102 mm Hg [normal range, 38-42 mm Hg]; Hco3- level, 29 mmol/L [normal range, 22-27 mmol/L]). Noninvasive ventilation was initiated. Imaging performed during the second ICU hospitalization included noncontrast chest CT (Fig 2), MRI of the chest without contrast enhancement (Fig 3), and fluorine 18 fluorodeoxyglucose PET/CT (Fig 4).

  • Open Access

    Diagnostic yield of viral multiplex PCR during acute exacerbation of COPD admitted to the intensive care unit: a pilot study

    by Costa Salachas, Cherifa Gounane, Gaëtan Beduneau, Julien Lopinto, Matthieu Turpin, Corinne Amiel, Antoine Cuvelier, Marie Gueudin, Guillaume Voiriot, Muriel Fartoukh

    Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is one of the leading causes of admission to the intensive care unit, often triggered by a respiratory tract infection of bacterial or viral aetiology. Managing antibiotic therapy in this context remains a challenge. Respiratory panel molecular tests allow identifying viral aetiologies of AECOPD. We hypothesized that the systematic use of a respiratory multiplex PCR (mPCR) would help antibiotics saving in severe AECOPD. Our objectives were to describe the spectrum of infectious aetiologies of severe AECOPD, using a diagnostic approach combining conventional diagnostic tests and mPCR, and to measure antibiotics exposure. The study was bicentric, prospective, observational, and included 105 critically ill patients with a severe AECOPD of presumed infectious aetiology, in whom a respiratory mPCR with a viral panel was performed in addition to conventional microbiological tests. Altogether, the microbiological documentation rate was 50%, including bacteria alone (19%), respiratory viruses alone (16%), and mixed viruses and bacterial species (16%). The duration of antibiotic therapy was shorter in patients without documented bacterial infection (5.6 vs. 9 days; P = 0.0006). This pilot study suggests that molecular tests may help for the proper use of anti-infective treatments in critically ill patients with severe AECOPD.


  • Open Access

    Respiratory multiplex PCR and procalcitonin to reduce antibiotic exposure in severe SARS-CoV-2 pneumonia: a multicentre randomized controlled trial

    by Muriel Fartoukh, Saad Nseir, Bruno Mégarbane, Yves Cohen, Antoine Lafarge, Damien Contou, Arnaud W. Thille, Louis-Marie Galerneau, Florian Reizine, Martin Cour, et al.


  • Open Access

    Feasibility of a repositioning schedule on pressure ulcer prevention in a French Intensive Care Unit: A pre and post-intervention pilot study

    by Daisy Daigné, Pierre-Yves Blanchard, Marie-Cécile Allain, Gwendoline Lambert, Séverine Rodriguez, Benjamin Tessier, Clarisse Blayau, Guillaume Voiriot, Laurence Bérard, Alexandra Rousseau, et al.